Subscribe to Newsletter
Diagnostics Omics, Bioinformatics

An Established Relationship

A new approach to creating a genomics database could move the field one step closer to curating the clinical exome for gene–disease relationships. The approach combines a human element – systematic literature review – with AI indexing of millions of published abstracts and full-text references with genetic information. Results of a study testing the new approach, presented at the Annual Clinical Genetics Meeting 2024, identified over 10,000 germline gene–disease relationships – more than half of which showed positive associations with a specific disease (1).

Mark Kiel, Chief Scientific Officer of Genomenon – and one of the study leads – explains the drivers for the project: “It is estimated that about one-third of all genomic analyses result in a variant of unknown significance in a gene with either known or unknown classification. If the gene is inaccurately classified, it can lead to incorrect diagnosis and treatment. Thus, the accurate and standardized classification of genes and genetic variants is imperative for advancing both clinical practice and scientific research.”

To ensure the robustness of the methodology, a comparison with other databases, such as ClinGen and GenCC, was conducted to assess the results in light of currently used standards. High concordance was observed between the databases, indicating the success of the new approach.

The proof-of-concept study has created a genetic evidence database that can be continuously and rapidly updated as new gene–disease relationships are established. “This will result in the resolution of genes of unknown significance (GUS) into more defined categories, such as the limited, strong, and definitive designations,” predicts Kiel. “As more GUS are resolved, the diagnostic workup and patient diagnosis rates are improved.” 

The study could prove particularly beneficial to patients with rare or unassigned genetic diseases. Kiel concludes, “This study will help clinical labs and clinicians in determining which genes should be tested and which should be omitted from testing for a particular disease, avoiding unnecessary testing, inaccurate diagnosis, and treatment.”

As to future developments, further AI capabilities will be implemented to the system to enhance expert human curation efficiency and the user experience.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. M Kiel et al, Gen Med, 2, Suppl. 1, Abstract O33 (2024).
About the Author
Helen Bristow

Combining my dual backgrounds in science and communications to bring you compelling content in your speciality.

Related Application Notes
Tumor Genomic Profiling with SureSelect Cancer Tumor-Specific Assays

| Contributed by Agilent

Comprehensive Genomic Profiling with SureSelect Cancer CGP Assay

| Contributed by Agilent

Automating Hybrid Capture NGS Workflow on AVENIO Edge

| Contributed by Roche

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register